MBF-015 is under clinical development by Medibiofarma and currently in Phase I for Huntington Disease. According to GlobalData, Phase I drugs for Huntington Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MBF-015 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MBF-015 overview

MBF-015 is under development for the treatment of synaptopathies (huntington disease, alzheimer's disease and parkinson's disease) . It acts by targeting histone deacetylase 1/2 (HDAC 1/2). It ia administered through oral route.

Medibiofarma overview

Medibiofarma is a biotechnology company, develops novel drugs for the treatment of cancer. The company focuses on virtual drug design, medicinal chemistry, in vitro pharmacology, intellectual property. Medibiofarma is headquartered in Noain, Navarra, Spain.

For a complete picture of MBF-015’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.